BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

Australia's Immutep inks oncology deal worth $349.5 M with Indian pharma firm Dr. Reddy's

December 8, 2025 | News

Dr. Reddy's receives exclusive rights to develop and commercialise Eftilagimod Alfa in all countries outside North America, Europe, Japan, and Greater China



Australia-based Immutep Limited and Dr. Reddy’s Laboratories, based in India, have announced that their respective wholly-owned subsidiaries, Immutep SAS and Dr. Reddy’s Laboratories SA, have entered into a strategic collaboration and exclusive licensing agreement for the development and commercialisation of Eftilagimod Alfa (efti) in all countries outside North America, Europe, Japan, and Greater China.

Efti is Immutep’s first-in-class novel immunotherapy that directly activates the immune system to fight cancer, which is under evaluation in TACTI-004 (KEYNOTE-F91), a registrational Phase III trial for the first-line therapy of advanced or metastatic non-small cell lung cancer. Efti is also being investigated in other indications including head & neck cancer, breast cancer, and soft tissue sarcoma.

As per the agreement, Immutep will receive from Dr. Reddy’s an upfront payment of $20 million (~AUD 30.2 million). It is also eligible to receive potential regulatory development and commercial milestone payments of up to $349.5 million (~AUD 528.4 million), plus double-digit royalties on commercial sales in these markets.

Immutep holds the global manufacturing rights to the product across all markets and will supply the product to Dr. Reddy’s in the licensed markets, while Immutep retains all rights to the product in the key pharmaceutical markets, including North America, Europe, and Japan.